Denosumab versus zoledronic acid in patients previously treated with zoledronic acid
- 1.1k Downloads
Denosumab and zoledronic acid are potent antiresorptives. In this study in patients pre-treated with zoledronic acid, denosumab achieved similar increases with zoledronic acid in lumbar spine BMD despite the more prominent reduction of bone turnover markers. Denosumab reversibly reduced endogenous RANKL.
We aimed to compare yearly changes in lumbar spine (LS) bone mineral density (BMD), bone turnover markers, free soluble receptor activator of nuclear factor kappaB ligand (sRANKL) and sclerostin levels between denosumab and zoledronic acid.
Postmenopausal women with low bone mass previously treated with zoledronic acid for 1 year were assigned to denosumab injection (n = 32) or zoledronic acid infusion (n = 26). Procollagen type 1 N-terminal propeptide (P1NP), C-terminal cross-linking telopeptide of type 1 collagen (CTx), sRANKL, and sclerostin levels were measured in serum samples obtained at baseline and 3, 6, and 12 months after denosumab injection or zoledronic acid infusion. LS BMD was measured at baseline and 12 months.
The mean LS increase was 4.5 and 4.4 % with denosumab and zoledronic acid, respectively (p = 0.560). Denosumab caused a larger decrease in CTx at 3 months (p < 0.001) and P1NP at 3 (p < 0.001), 6 (p = 0.021), and 12 months (p = 0.042). Denosumab significantly decreased sRANKL by 87.4 % at 3 months (p < 0.001). Sclerostin levels were not changed with either intervention (p = 0.162 and p = 0.214, respectively).
In patients previously treated with zoledronic acid, denosumab reduces bone turnover more than zoledronic acid, but the increases in LS BMD are comparable. Furthermore, denosumab administration results in reversible inhibition of the metabolically significant endogenous free soluble RANKL levels. Serum sclerostin is not affected by either agent.
KeywordsBone mineral density Bone turnover markers Denosumab RANKL Sclerostin Zoledronic acid
We thank Roche Diagnostics Hellas for providing us the kits for the measurements of CTx, P1NP, PTH, and 25(OH)D.
Conflicts of interest
Athanasios D. Anastasilakis has received lecture fees and research grant from Amgen and lecture fees from Lilly; Stergios A. Polyzos has received lecture fee and research grant from Amgen; Athina Gkiomisi, Zacharias G. Saridakis, Dimitrios Digkas, Ilias Bisbinas, Grigorios T. Sakellariou, Athanasios Papatheodorou, and Panagiotis Kokkoris have nothing to declare. Polyzois Makras has received lecture fees and research grants from Amgen, and lecture fees from Glaxo, Lilly, Pfizer, Leo, Genesis, ELPEN, VIANEX. Neither Amgen nor Novartis had any implication in any stage of this study (study’s conception and design, analysis and interpretation of data, drafting, or revising the manuscript).
- 4.Stolina M, Dwyer D, Middleton S, Adamu S, Ominsky MS, Zack D, Kostenuik PJ (2007) OPG prevents osteopenia in arthritic rats via different mechanisms than bisphosphonate therapy. J Bone Miner Res 22(Suppl 1):S475Google Scholar
- 10.Brown JP, Roux C, Ho PR et al (2014) Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate. Osteoporos Int 25:1953–1961PubMedGoogle Scholar
- 12.Anastasilakis AD, Polyzos SA, Gkiomisi A, Bisbinas I, Gerou S, Makras P (2013) Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naïve postmenopausal women with low bone mass: a randomized, head-to-head clinical trial. J Clin Endocrinol Metab 98:3206–3212CrossRefPubMedGoogle Scholar
- 18.Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972–980CrossRefPubMedGoogle Scholar